Abstract
Background and purposeThis study investigated the prognostic role of PD-L1 expression, PD-1+ tumor-infiltrating lymphocytes (TILs), and the ratio of PD-1+/CD8+ TILs in extrahepatic bile duct (EHBD) cancer. Materials and methodsWe analyzed 83 patients with EHBD cancer who underwent curative surgery plus fluoropyrimidine-based chemoradiotherapy (CRT). Expressions of PD-L1, PD-1, and CD8 were assessed by immunohistochemistry. ResultsFifty-six (68%) patients were PD-L1-positive, and its lower expression level was associated with hilar tumor location (P=0.044). A higher ratio of PD-1+/CD8+ TILs was associated with poorer overall survival (OS) (P=0.032), relapse-free survival (RFS) (P=0.024), and distant metastasis-free survival (DMFS) (P=0.039) in Kaplan–Meier analyses, but survival differences were not observed according to the PD-L1 expression level. With Cox proportional hazards models, the ratio of PD-1+/CD8+ TILs was the independent prognostic factor in OS (HR 2.47, 95% CI 1.04–5.86), RFS (HR 2.41, 95% CI 1.08–5.41), and DMFS (HR 2.67, 95% CI 1.00–7.11) after adjusting for other significant clinicopathologic variables. ConclusionA strong survival impact of the ratio of PD-1+/CD8+ TILs was observed in EHBD cancer. In the poor prognostic subgroup, the blockade of the immune checkpoint in combination with conventional multimodality treatment needs to be considered.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
